Upregulation of Checkpoint Ligand Programmed Death-Ligand 1 in Patients with Paroxysmal Nocturnal Hemoglobinuria Explained by Proximal Complement Activation.
Saved in:
| Title: | Upregulation of Checkpoint Ligand Programmed Death-Ligand 1 in Patients with Paroxysmal Nocturnal Hemoglobinuria Explained by Proximal Complement Activation. |
|---|---|
| Authors: | Anliker M; Central Institute for Medical and Chemical Laboratory Diagnosis, University Hospital, Innsbruck, Austria., Drees D; Institute of Transfusion Medicine, University of Ulm, Ulm, Germany.; Institute of Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service, Baden-Württemberg-Hessen and University Hospital of Ulm, Ulm, Germany., Loacker L; Central Institute for Medical and Chemical Laboratory Diagnosis, University Hospital, Innsbruck, Austria., Hafner S; Institute of Pharmacology of Natural Products and Clinical Pharmacology, Ulm University, Ulm, Germany., Griesmacher A; Central Institute for Medical and Chemical Laboratory Diagnosis, University Hospital, Innsbruck, Austria., Hoermann G; Central Institute for Medical and Chemical Laboratory Diagnosis, University Hospital, Innsbruck, Austria.; MLL Munich Leukemia Laboratory, Munich, Germany., Fux V; Central Institute for Medical and Chemical Laboratory Diagnosis, University Hospital, Innsbruck, Austria., Schennach H; Central Institute of Blood Transfusion and Immunology, University Hospital Innsbruck, Innsbruck, Austria., Hörtnagl P; Central Institute of Blood Transfusion and Immunology, University Hospital Innsbruck, Innsbruck, Austria., Dopler A; Institute of Pharmacology of Natural Products and Clinical Pharmacology, Ulm University, Ulm, Germany., Schmidt S; Department of Internal Medicine V, Medical University of Innsbruck, Innsbruck, Austria; and., Bellmann-Weiler R; Department of Internal Medicine II, Innsbruck Medical University, Innsbruck, Austria., Weiss G; Department of Internal Medicine II, Innsbruck Medical University, Innsbruck, Austria., Marx-Hofmann A; Institute of Transfusion Medicine, University of Ulm, Ulm, Germany.; Institute of Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service, Baden-Württemberg-Hessen and University Hospital of Ulm, Ulm, Germany., Körper S; Institute of Transfusion Medicine, University of Ulm, Ulm, Germany.; Institute of Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service, Baden-Württemberg-Hessen and University Hospital of Ulm, Ulm, Germany., Höchsmann B; Institute of Transfusion Medicine, University of Ulm, Ulm, Germany.; Institute of Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service, Baden-Württemberg-Hessen and University Hospital of Ulm, Ulm, Germany., Schrezenmeier H; Institute of Transfusion Medicine, University of Ulm, Ulm, Germany; christoph.schmidt@uni-ulm.de h.schrezenmeier@blutspende.de.; Institute of Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service, Baden-Württemberg-Hessen and University Hospital of Ulm, Ulm, Germany., Schmidt CQ; Institute of Pharmacology of Natural Products and Clinical Pharmacology, Ulm University, Ulm, Germany; christoph.schmidt@uni-ulm.de h.schrezenmeier@blutspende.de. |
| Source: | Journal of immunology (Baltimore, Md. : 1950) [J Immunol] 2022 Mar 01; Vol. 208 (5), pp. 1248-1258. Date of Electronic Publication: 2022 Feb 16. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Oxford University Press Country of Publication: England NLM ID: 2985117R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1550-6606 (Electronic) Linking ISSN: 00221767 NLM ISO Abbreviation: J Immunol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
